SP1 serves as a therapeutic target against oral cancer (Shin et al., 2012; Yu et al., 2013; Chae et al., 2014; Sun et al., 2016; Zhang et al., 2019; Zhao et al., 2019; Gao et al., 2020; Liu et al., 2020). Here, SP1 is linked to lip and oral cavity carcinoma.